Two States Require Industry To Pay For Ongoing Drug Take-Back Programs
This article was originally published in The Pink Sheet & The Rose Sheet
Consumer Healthcare Products Association looks to stem expansion of state-mandated drug take-back programs with programs that use existing facilities and infrastucture and don't require industry funidng, says state affairs VP Carlos Gutierrez. State bills limiting sales of DXM to minors and expansion of the NPLEx system to track PSE sales also are on CHPA’s radar.
You may also be interested in...
OTC industry trade groups will more aggressively push for an education program to encourage proper disposal of Rx and OTC drugs as states consider mandating industry-funded takeback programs and a patchwork of local ordinances expands.
CHPA President and CEO Scott Melville says 2015 is the “quietest” in five years for state legislation on the sale of pseudoephedrine, a testament to NPLEx. Bills for Rx-only PSE sales introduced in four states this year failed.